RxDoctor Payments Data

Brooks Kimmis

Dermatology · E Greenwich, RINPI 1043715659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 27.1% of the total. 2025 is the largest year on record at $941, more than ten times the $59 reported in 2019.

$3,094in general payments, 2019–2025

Across 117 payments — averaging $26.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$839
  • LEO Pharma Inc.$583
  • Sanofi$454
  • Lilly USA, LLC$283
  • Novartis$235
  • Johnson & Johnson$209
  • plus $491 from 10 others

What the payments were for

  • Travel & lodging$221%
  • Food & beverage$2,85992%
  • Education$2137%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,094 in reported general payments places this provider in the 65th percentile of 61 dermatology providers in Rhode Island.

See all dermatology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$625,948
Medicare patients
612
Services billed
6,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$281,569
Cosentyx Sensoready (2 Pens)Secukinumab17$159,889
Dupixent PenDupilumab20$103,690
Clobetasol Propionate136$6,084
Ketoconazole249$5,885
Tacrolimus35$4,123
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc103$3,957
Fluorouracil67$3,880
Triamcinolone Acetonide155$2,023
Mycophenolate Mofetil14$1,936
Metronidazole45$1,798
Imiquimod24$823
Permethrin15$794
Clindamycin Phosphate24$711
Desonide13$656

Paid to pharmacies, not to this prescriber.

Other dermatology in E Greenwich

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →